We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blocking the Acsl14 Enzyme Prevents Ferroptosis-Linked Cell Death

By Gerald M. Slutzky, PhD
Posted on 25 Nov 2016
Inhibiting the enzyme Acsl4 (acyl-CoA synthetase long-chain family member 4), which is involved in fatty acid metabolism, has been postulated to be a viable therapeutic approach to preventing ferroptosis-related diseases.

Ferroptosis, a poorly understood form of programmed cell death, has been implicated in the pathological cell death found in neuronal and kidney tissues. More...
It may also be possible to selectively trigger ferroptosis in certain cancer cells. Previously, only a few essential molecules, such as glutathione peroxidase 4 (Gpx4), have been implicated in the ferroptotic process.

Investigators at Helmholtz Zentrum München (Germany) applied two independent approaches - a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines - to generate new details as to how ferroptosis works.

They reported in the November 14, 2016, online edition of the journal Nature Chemical Biology that ACSL4 was as an essential component for ferroptosis execution. Specifically, cells in which the genes for both Gpx4 and Acsl4 proteins had been removed showed marked resistance to ferroptosis. Mechanistically, Acsl4 enriched cellular membranes with long polyunsaturated omega-6 fatty acids. Targeting Acsl4 with thiazolidinediones, a class of antidiabetic compound, prevented tissue destruction in a mouse model of ferroptosis, Moreover, Acsl4 was preferentially expressed in a panel of basal-like breast cancer cell lines and predicted their sensitivity to ferroptosis.

"The individual mechanisms involved in this type of cell death remain only partly understood, and our findings make an important contribution towards a better understanding of ferroptotic cell death," said senior author Dr. Marcus Conrad, head of a research group at the institute of developmental genetics at the Helmholtz Zentrum München. "Our intriguing insights that the Acsl4 enzyme plays a substantial role in the process of cell death provide novel cues for yet-unrecognized therapeutic approaches towards inhibiting ferroptosis in degenerative diseases or inducing ferroptosis in certain tumor diseases. In particular, tumors that are otherwise very difficult to treat with standard chemotherapy might be amenable for ferroptosis therapy."

Related Links:
Helmholtz Zentrum München


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
New
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.